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Objective: Identify characteristics of Kentucky community 
pharmacists and community pharmacists’ practice 
environment associated with utilization of the Kentucky All 
Schedule Prescription Electronic Reporting Program 
(KASPER). 
Methods: Surveys were mailed to all 1,018 Kentucky 
pharmacists with a KASPER account and an additional 
1,000 licensed pharmacists without an account. Bivariate 
analyses examined the association between KASPER 
utilization and practice type (independent or chain) and 
practice location (rural or urban). A multivariate Poisson 
regression model with robust error variance estimated risk 
ratios (RR) of KASPER utilization by characteristics of 
pharmacists’ practice environment. 
Results: Responses were received from 563 pharmacists 
(response rate 27.9%). Of these, 402 responses from 
community pharmacists were included in the analyses. A 
majority of responding pharmacists (84%) indicated they 
or someone in their pharmacy had requested a patient’s 
controlled substance history since KASPER’s inception. 
Bivariate results showed that pharmacists who practiced in 
independent pharmacies reported greater KASPER 
utilization (94%) than pharmacists in chain pharmacies 
(75%; p<0.001). Multivariate regression results found 
utilization of KASPER varied significantly among practice 
environments of community pharmacists with those who 
practiced in an urban location (RR: 1.11; [1.01–1.21]) or at 
an independent pharmacy (RR: 1.27; [1.14–1.40]) having 
an increased likelihood of KASPER utilization. 
Conclusion: Utilization of KASPER differs by community 
pharmacists’ practice environment, predominantly by 
practice type and location. Understanding characteristics 
of community pharmacists and community pharmacists’ 
practice environment associated with PDMP use is 
necessary to remove barriers to access and increase 
utilization thereby increasing PDMP effectiveness. 
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The abuse and misuse of prescription drugs is a 
major public health concern1 and characterized as 
an epidemic in the US.2 In an effort to address the 
problem of prescription drug abuse and diversion, 
states have enacted legislation for the creation of 
prescription drug monitoring programs (PDMPs) to 
track controlled substance (CS) dispensing.3 
Reports detailing a patient’s CS prescription history 
can be accessed upon request, or proactively 
distributed depending upon state regulations. As of 
December 2013, PDMPs are operational in 48 
states.4 
In 1999, Kentucky implemented the Kentucky All 
Schedule Prescription Electronic Reporting 
(KASPER) program allowing prescribers, 
pharmacists, and law enforcement officials to 
request reports providing detailed information 
regarding an individual’s CS prescription history. In 
2005, a fully electronic version of KASPER was 
launched allowing pharmacists and prescribers to 
receive KASPER reports in real-time, permitting 
them to utilize a patient’s CS prescription history to 
make treatment decisions at the point of care. 
Characteristics and opinions of healthcare 
professionals who utilize PDMP reports have been 
assessed. In Kentucky, satisfaction surveys 
conducted in 2004, 2006, and 2010 captured 
prescriber, dispenser, and law enforcement 
opinions of KASPER.5-7 Results showed the 
majority of KASPER users were satisfied with the 
system and believed it to be effective, efficient, 
accurate, and useful to identify CS abuse and 
diversion. A 2010 study of Ohio community 
pharmacists examined factors influencing 
enrollment in the state’s PDMP.8 Factors influencing 
the decision to enroll were ability to assist in 
decreasing doctor shopping and drug abuse, 
Internet access, and receiving education about the 
PDMP. A survey of Florida pharmacists assessing 
attitudes regarding implementation of a PDMP 
found that responding pharmacists agreed a PDMP 
should be implemented and would reduce the 
incidence of doctor shopping.9 Most recently, Green 
and colleagues surveyed pharmacist users of 
PDMPs in Connecticut and Rhode Island and 
concluded pharmacists use PDMP data to screen 
for abuse and doctor shopping, but PDMP use had 
limited impact on other aspects of pharmacy 
practice including counseling patients on safer 
opioid use, and providing guidance on proper 
storage and disposal of unused medications.10 The 
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impact of practice setting was not assessed and 
noted as being an important limitation to the study 
as “practice setting may influence the frequency 
with which pharmacists access PDMPs and how 
PDMP information obtained is used”.10 
Studies evaluating the effectiveness of PDMPs 
suggest they successfully reduce the supply of 
CS.11,12 This reduction in supply may not be 
associated with improved health outcomes, 
specifically reductions in drug overdose mortality 
rates.13,14 However, some states with rigorous 
PDMPs report recent reductions in overdose 
mortality15,16 and increasing evidence suggests that 
utilization of PDMP reports reduces “doctor 
shopping”.17 Because policies regarding access to 
and utilization of PDMP reports by healthcare 
providers vary among states4, it is possible that 
PDMP effectiveness is limited due to inadequate 
use of PDMP reports at the point of care. A 2010 
independent evaluation of the KASPER program 
revealed 16% of licensed pharmacists and 27.5% of 
licensed CS prescribers were registered with the 
PDMP.18 These registration numbers parallel 
estimates reported by other states, suggesting that 
overall less than 25% of healthcare professionals 
access PDMPs to obtain patient reports.19 
Increased utilization of PDMP reports by healthcare 
professionals, including pharmacists, could assist 
PDMPs in meeting their stated objectives. 
Understanding characteristics associated with 
PDMP use may assist in developing strategies to 
increase utilization, thereby increasing PDMP 
effectiveness. The purpose of this study was to 
examine the association between characteristics of 
pharmacists and pharmacists’ practice environment 
with KASPER use, and determine if specific 




Survey methodology elicited community 
pharmacists’ perceptions regarding KASPER’s 
impact on CS dispensing and effectiveness in 
Kentucky in 2009. Survey items were developed by 
health policy researchers and academic 
pharmacists based on reviews of previous PDMP 
surveys5-7 and discussions with KASPER staff. The 
survey instrument was designed to take 
approximately ten minutes to complete and was 
pilot tested to verify clarity and length. All 1,018 
Kentucky pharmacists with a KASPER account at 
the time of the survey, and 1,000 additional 
pharmacists without an account randomly selected 
from a list of 6,600 actively licensed pharmacists in 
Kentucky were contacted by mail to complete a 15-
item survey. 
The survey packet included a postcard with a link to 
an electronic version of the survey and an 
identification code giving the pharmacist the option 
of returning the survey via mail or completing it 
online. Reminder postcards and second surveys 
were sent two weeks after the initial mailing. Survey 
protocol was approved by the Institutional Review 
Board at the University of Kentucky and the 
Kentucky Cabinet for Health and Family Services. 
Bivariate analyses examined associations between 
practice type (independent versus chain) and 
practice location (rural versus urban) with 
pharmacists and practice environment 
characteristics. Practice type classifications were 
based on how the pharmacist described their 
practice, with independent, chain, and supermarket 
pharmacies considered community pharmacies. For 
this analysis supermarket pharmacies were grouped 
with chain pharmacies. Rural/urban classifications 
were based on the 2003 Rural-Urban Continuum 
(RUC) Codes developed by the US Department of 
Agriculture.20 Counties with an RUC code of 1, 2, or 
3 were grouped as urban while counties with an 
RUC code of 4 or greater were considered rural.20 
Statistical significance was evaluated using the 
Wald chi-square for categorical demographic data. 
Data normality for continuous variables was tested 
using the Shapiro-Wilk test and differences 
assessed using the nonparametric Kruskal-Wallis 
test. 
A Poisson regression model using a robust error 
variance adjusting for characteristics of 
pharmacists’ practice environment, years since 
licensure, daily CS dispensing volume, and 
perceived effectiveness of KASPER estimated the 
relative risk and associated confidence intervals (CI) 
of KASPER utilization by community pharmacists. 
For this study KASPER utilization was defined as 
having requested information regarding a patient’s 
CS prescription history since the inception of 
KASPER. Covariates were hypothesized to predict 
KASPER utilization (e.g., pharmacists with more 
years since licensure less likely to use KASPER; 
higher CS dispensing associated with greater 
likelihood to utilize KASPER; perception of KASPER 
being an effective tool associated with increased 
likelihood of utilization). Statistical analyses were 
conducted in Stata v12.0 (StataCorp LP, College 
Station, TX). The a priori level of significance was 
set at 0.05. 
 
RESULTS  
Descriptive and Bivariate 
Surveys were mailed to 2,018 pharmacists in 
Kentucky of which 563 were returned (response 
rate 27.9%). Thirteen returned surveys were 
deemed incomplete and removed from further 
analysis. Another 26 observations were excluded 
because the respondent indicated they practiced 
outside Kentucky, and 120 were excluded because 
the pharmacist did not specify their practice type as 
a community pharmacy. Two additional 
observations were excluded because the question 
pertaining to KASPER use was not answered. 
Overall, 402 observations were included in the 
analyses. 
Of the responding pharmacists, 339 (84%) indicated 
they or personnel in their pharmacy had requested 
a patient’s CS prescription history from KASPER 
since the inception of the program. Among the 
pharmacists who had not requested CS prescription 
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histories, the most common reason identified for not 
using KASPER was “I do not have Internet access 
to request KASPER reports at my practice site” 
(n=30). All pharmacists who indicated lack of 
Internet access as the primary barrier to using 
KASPER identified their practice type as chain 
pharmacy. Baseline characteristics and KASPER 
utilization for responding pharmacists by practice 
type (independent and chain) and practice location 
(rural and urban) are presented in Table 1. 
A significant relationship was found in the bivariate 
comparison between use of KASPER and practice 
type, with a greater proportion of independent 
pharmacists having utilized KASPER (94%) than 
chain pharmacists (75%, p<0.001). Daily CS 
dispensing volume varied significantly with chain 
pharmacies dispensing more CS per day (median: 
50, IQR: 30–100) than independent pharmacies 
(median: 40, interquartile range (IQR): 22–60, 
p=<0.001). Seventy percent (70%) of chain 
pharmacists stated they practiced in an urban 
location while only 38% of independent pharmacists 
indicated they practiced in an urban location 
(p<0.001). Responding pharmacists at independent 
pharmacies reported being licensed for more years 
(median: 27, IQR: 16–35) than chain pharmacists 
(median: 15, IQR: 5–29, p<0.001), respectively. 
Bivariate comparisons revealed no significant 
association between practice location and KASPER 
use (p=0.878). Pharmacists in rural locations, 
compared to urban locations, were more likely to 
practice in an independent pharmacy (66% vs. 34%, 
p<0.001), and also reported being licensed for a 
longer period of time (median: 24, IQR: 10–34, 
median: 19, IQR: 8–31, p=0.037). 
Responding pharmacists perceived KASPER as an 
effective tool to reduce drug abuse and diversion 
(92%; n=365) as well as doctor shopping (90%; 
n=350) in Kentucky. No difference in perceived 
effectiveness based on practice type was observed, 
however, a greater proportion of pharmacists in 
urban locations viewed KASPER as an effective tool 
to reduce drug abuse/diversion than pharmacists in 
rural locations (93% vs. 86%, p=0.041). 
Multivariate Poisson Regression Model 
Results from the Poisson regression model are 
presented in Table 2. Adjusted for the covariates 
listed in Table 2, community pharmacists in urban 
locations were 11% more likely to utilize KASPER 
than pharmacists in rural locations (p=0.032). After 
adjusting for the covariates, independent 
pharmacists were 27% more likely to utilize 
Table 1. Baseline Characteristics of Community Pharmacists by Practice Type and Practice Location 
Variable 




N = 202 
p-value 
Rural 
N = 173 
Urban 
N = 217 
p-value 
KASPER Utilization  
Requested Reports 187 94% 152 75% <0.001* 145 84% 183 84% 0.890 
Practice Location  
Rural 115 58% 58 29% <0.001* - - - - - 
Urban 75 38% 142 70% <0.001* - - - - - 
Practice Type  
Independent - - - - - 115 66% 75 34% <0.001* 
Chain - - - - - 58 33% 142 65% <0.001* 
Years in Practice  
Median Years (IQR)a 27 16(35) 15 5(29) <0.001* 24 10(34) 19 8(31) 0.028* 
CS Dispensing Behavior  
Median CS dispensed per day (IQR)a 40 22(60) 50 30(100) <0.001* 50 25(75) 45 26(75) 0.391 
Perceived Effectiveness of KASPER  
Reducing Drug Abuse and Diversion 176 88% 184 91% 0.219 148 86% 201 93% 0.042* 
Reducing Doctor Shopping 172 86% 174 86% 0.675 149 86% 186 86% 0.734 
* Denotes statistical significance at the 5% level. a IQR: Interquartile range 
Table 2. Predicting Community Pharmacist Use of KASPER (Poisson regression model) 
Variables Relative Risk p-value 95%CI 
Practice Location 
Rural Ref 
Urban  1.11* 0.037 1.01-1.21 
Practice Site 
Chain Ref 
Independent  1.27* <0.001 1.15 - 1.40 
Years in Practice 
Yearsa  0.96* 0.050 0.93 - 1.00c
CS Dispensing Behavior 
CS Dispensed per Dayb 1.00 0.297 1.00c - 1.01 
Perceived PDMP Effectiveness Reducing Drug Abuse and Diversion 
Ineffective Ref 
Effective 1.06 0.580 0.87 – 1.28 
Perceived PDMP Effectiveness Reducing Doctor Shopping 
Ineffective Ref 
Effective 1.12 0.224 0.93 – 1.36 
*Denotes statistical significance at the 5% level
aYears was divided by 10 to show the impact of practicing an additional 10 years 
bCS dispensed per day was divided by 10 to show the impact of dispensing an additional 10 CS per day 
c Confidence interval includes 1.00 due to rounding 
95%CI = 95% Confidence Interval 
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KASPER than chain pharmacists (p<0.001). A 
negative relationship was observed between the 
years since licensure and the likelihood of a 
pharmacist using KASPER (p=0.05). Neither CS 
dispensing volume nor perceived KASPER 




Prescription drug monitoring programs have been 
implemented by states to address the prescription 
drug abuse crisis in the US. This study’s purpose 
was to examine the association between 
characteristics of community pharmacists and 
pharmacists’ practice environment with KASPER 
use, and determine if specific characteristics 
increased the likelihood of KASPER utilization. After 
controlling for confounding covariates, our 
multivariate results indicate that pharmacists who 
practiced in urban locations or at independent 
pharmacies were more likely to utilize KASPER 
than their counterparts in rural locations or chain 
pharmacies. The finding that urban pharmacists 
were more likely to utilize KASPER than rural 
pharmacists is somewhat surprising as prescription 
drug abuse is most prevalent in rural areas.21-23 The 
high prevalence of prescription drug abuse in rural 
areas may also explain why the bivariate analysis 
found a lower proportion of rural pharmacists 
perceived KASPER as an effective tool to reduce 
drug abuse and diversion. However, pharmacists’ 
perceptions concerning the effectiveness of 
KASPER did not impact the likelihood of utilization 
in the multivariate analysis.  
Lack of Internet access was cited as the primary 
reason for not requesting a KASPER report and is 
consistent with previous surveys.8,10 Considering 
that all responding pharmacists who indicated lack 
of Internet access as the primary reason for not 
using KASPER were chain pharmacists, it is not 
surprising that chain pharmacists were less likely to 
use KASPER. In fact, it is possible that this factor 
(i.e., lack of Internet access) may outweigh the 
impact of location and years-of-practice. Although 
not specifically addressed in this survey, workflow 
issues and corporate policies within chain 
pharmacies are likely different from those in 
pharmacies independently owned and operated. 
Thus, to increase PDMP utilization, other barriers in 
chain pharmacies should be explored.  
The response rate of 27.9% is considered low, 
though consistent with other pharmacist 
surveys.8,10,24 The study sample may not be 
representative of all community pharmacists in 
Kentucky as views of respondents may differ from 
non-responders and pharmacists familiar with 
KASPER may have been more inclined to 
participate. Due to the anonymous nature of the 
survey, comparisons of responders and non-
responders were not possible. Additionally, the 
sample was limited to Kentucky community 
pharmacists and may not be generalizable to other 
states. This study analyzed a survey administered 
in 2009 and current KASPER utilization by Kentucky 
community pharmacists may have been impacted 
by improvements to the system, changes in 
corporate policies, and an increased awareness of 
the program. To protect anonymity extensive 
individual/pharmacist level questions (i.e. 
demographics) were not asked. Also, due to the 
cross-sectional design of this study an association 
between variables does not imply causality. 
 
CONCLUSIONS 
Utilization of KASPER at the point of dispensing 
varied significantly among community pharmacists 
and was influenced by characteristics of 
pharmacists’ practice environment including 
practice type and practice location. For PDMPs to 
meet their objectives of curbing CS abuse and 
diversion, increased utilization of reports by 
healthcare professionals, including community 
pharmacists, for treatment decisions is warranted. 
Understanding characteristics associated with 
PDMP use may assist in developing strategies to 
remove barriers and increase utilization, thereby 
increasing the effectiveness of PDMPs. 
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UTILIZACIÓN DEL PROGRAMA DE 
MONITORIZACIÓN DE LA PRESCRIPCIÓN DE 
MEDICAMENTOS EN LAS FARMACIAS 
COMUNITARIAS DE KENTUCKY 
 
RESUMEN 
Objetivo: Identificar las características de las farmacias 
comunitarias y del entorno de práctica de las farmacias 
comunitarias relacionadas con la utilización del 
Kentucky All Schedule Prescription Electronic Reporting 
Program (KASPER). 
Métodos: Se enviaron cuestionarios a todos los 1.018 
farmacéuticos con cuenta en el KASPER y a un total 
adicional de 1.000 farmacéuticos sin cuenta. Se examinó 
la asociación entre la utilización de KASPER y el tipo de 
ejercicio (independiente o de cadena) la localidad (rural o 
urbana) con análisis bivariado. Mediante un modelo de 
regresión multivariada de Poisson con varianza de error 
robusta se estimaron los ratios de riesgo (RR) de la 
utilización de KASPER con las características del 
entorno de práctica de los farmacéuticos. 
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Resultados: Se recibieron respuestas de 563 
farmacéuticos (tasa de respuesta 27,9%). De esos, 402 
respuestas de farmacéuticos comunitarios se incluyeron 
en el análisis. La mayoría de los respondentes (84%) 
indicó que ellos o alguien de su farmacia habían 
solicitado una historia de substancias controladas de un 
paciente desde que se creó KASPER. El análisis 
bivariado demostró que los farmacéuticos que ejercían en 
farmacias independientes comunicaban una mayor 
utilización de KASPER (94%) que los farmacéuticos de 
cadenas (75%; p<0,001). Los resultados de la regresión 
multivariada encontraron que la utilización de KASPER 
variaba significativamente entre los entornos de práctica 
de los farmacéuticos comunitarios que trabajaban en 
localidades urbanas (RR: 1,11; [1,01–1,21]) o los de 
farmacias independientes (RR: 1,27; [1,14–1,40]) que 
tenían una mayor probabilidad de utilización de 
KASPER. 
Conclusión: La utilización de KASPER difiere en los 
ambientes de práctica de los farmacéuticos comunitarios, 
principalmente por tipo de establecimiento y 
localización. Es necesario entender las características de 
los farmacéuticos comunitarios y de los entornos de 
práctica de las farmacias comunitarias asociadas con el 
uso de programas de monitorización de la prescripción 
(PDMP) para eliminar las barreras de acceso y aumentar 
la utilización incrementando así la efectividad del PDMP. 
 
Palabras clave: Detección de Abuso de Sustancias; 
Sistemas de Registro de Reacción Adversa a 
Medicamentos; Notificación Obligatoria; Servicios de 
farmacias comunitarias; Ejercicio profesional; 
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